Cardiol Therapeutics (TSE:CRDL) Trading Down 3.5% – What’s Next?

Cardiol Therapeutics Inc. (TSE:CRDL) shares fell 3.5% on Monday . The company traded as low as C$1.35 and last traded at C$1.39. 117,719 shares were traded during trading, an increase of 9% from the average session volume of 107,964 shares. The stock had previously closed at C$1.44.

Cardiol Therapeutics Price Performance

The company has a quick ratio of 6.84, a current ratio of 2.49 and a debt-to-equity ratio of 1.59. The company has a market capitalization of C$140.31 million, a P/E ratio of -2.94 and a beta of 1.31. The company’s 50-day simple moving average is C$1.51 and its 200 day simple moving average is C$1.65.

Cardiol Therapeutics (TSE:CRDL) last issued its quarterly earnings results on Thursday, November 13th. The company reported C($0.12) earnings per share (EPS) for the quarter. As a group, sell-side analysts expect that Cardiol Therapeutics Inc. will post -0.49 earnings per share for the current fiscal year.

About Cardiol Therapeutics

Cardiol Therapeutics Inc (NASDAQ: CRDL) (TSX: CRDL) is a clinical-stage life sciences company focused on the research and clinical development of anti-inflammatory and anti-fibrotic therapies for the treatment of heart disease. The Company’s lead drug candidate, CardiolRxTM (cannabidiol) oral solution, is pharmaceutically manufactured and in clinical development for use in the treatment of heart disease.